Cellcolabs

Cellcolabs is positioned as an industrial-scale manufacturer of GMP-grade mesenchymal stem cells, aiming to solve the critical bottleneck of cell supply in regenerative medicine. Leveraging over 25 years of foundational research from the Karolinska Institute, the company has industrialized a scientifically validated production protocol to ensure potency, purity, and consistency. It operates as a B2B supplier and collaborator for global clinical research, supporting a broad pipeline of potential therapeutic applications across immunology, neurology, orthopedics, and more. The company is privately held, employs over 80 people, and has established numerous research partnerships.

Industrial-scale, GMP-certified manufacturing platform for bone marrow-derived mesenchymal stem cells (MSCs). Features a scientifically validated protocol from Karolinska Institutet, ensuring consistent production of potent, phenotypically defined, genetically stable, and sterile cells cryopreserved at Passage 3.

Cellcolabs competes with other contract development and manufacturing organizations (CDMOs) and specialized cell therapy suppliers. Its key differentiators are its direct lineage from decades of academic research at Karolinska, its specific focus on MSCs, its early-mover GMP certification from the Swedish MPA, and its mission to provide affordable, industrial-scale supply.